IP GROUP Access to a section of the platform will be enabled via a new mobile app at the American Society of Human Genetics (ASHG) 2015 conference, October 6th-10th, Baltimore, Maryland
Genomics plc ('Genomics'), a leading genome analytics company, is developing algorithms, curated data resources, and software solutions to uncover the relationships between genetic variation and human traits and diseases. Genomics is allowing delegates at the American Society of Human Genetics (ASHG) 2015 conference to access part of its genetic association platform via a new mobile app weSNP (http://www.genomicsplc.com/wesnp/), for Android, iPhone and iPad devices, which is being made available for demonstration purposes at the conference.
DNA sequence variations, or single nucleotide polymorphisms (SNPs), have been associated with a wide range of human diseases and traits. Analysis of this information provides a powerful tool for improving drug development pipelines. Many studies have captured data about SNPs and their association with particular traits and diseases (phenotypes), but integrating this information across studies is challenging.
Genomics' team of bioinformaticians and statistical geneticists has developed a database including over 250 studies and 7 million SNPs gathered from various different sources, combining proprietary algorithms and software to integrate the data and to identify the relationships between genetic variations and human health outcomes. The mobile app will allow conference delegates to gain a sense of the available resources by providing a window into the company's data and analyses, to see the structure of genetic association across five phenotypic categories and over 160 individual phenotypes.
John Colenutt, CEO at Genomics plc, said: 'At Genomics, we have created our integrated genetic association platform as a powerful tool to improve human health and healthcare by harnessing the insights into human biology provided by genetic data. We have developed weSNP for the ASHG meeting to demonstrate to potential customers and partners the real value of sophisticated analyses of integrated genomic databases.'
Genomics has three partnerships with large pharmaceutical companies and, in the clinical genomics space, it is a Platform Provider for Genomics England, the company undertaking the 100,000 Genomes project in the UK.
weSNP will be available from 6th-10th October, 2015, from the Apple App Store and Google Play. To find out more, or to download the mobile app, please visit http://www.genomicsplc.com/wesnp/
ENDS
Follow Genomics plc on Twitter (@genomicsplc) for updates on the weSNP app. The Twitter hashtag for the app is #wesnp, and the Twitter hashtags for the ASHG conference are #ASHG2015 and #ASHG15.
For high resolution images please contact lorna.cuddon@zymecommunications.com
For further information please contact:
Zyme Communications
Lorna Cuddon
Tel: +44 (0)7811996942
Email: lorna.cuddon@zymecommunications.com
About Genomics plc
http://www.genomicsplc.com/
Genomics was founded by four leading Oxford academics, including Professor Peter Donnelly, Director of The Wellcome Trust Centre for Human Genetics, and Professor Gil McVean, Director of The Big Data Institute. The Company has developed a unique platform for genomic sequence data analysis and interpretation which combines world-leading expertise in statistical analysis and data mining with a unique integrated database linking genotypes and phenotypes. Genomics England, the company running the UK project to undertake whole genome sequencing of 100,000 patients in the National Health Service, has appointed Genomics plc as a Platform Provider and has also awarded the Company three SBRI grants. Genomics plc is also working with three major pharmaceutical companies to bring the benefits of genomic analysis to their drug development processes. The Company is supported by major investors, including IP Group, Invesco Perpetual, Woodford Investment Management and Lansdowne Partners.
|
distributed by
|
